Bioassays for anticancer activities

Methods in Molecular Biology

Volumn 1055, Issue , 2013, Pages 191-205

  McCauley, Janice ^a   Zivanovic, Ana ^a   Skropeta, Danielle ^a  

^a UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

Anticancer activity; Cytotoxicity; Enzyme inhibition; Human cancer cell lines; Kinases; MTS MTT assays

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 3 (4,5 DIMETHYLTHIAZOL 2 YL) 5 (3 CARBOXYMETHOXYPHENYL) 2 (4 SULFOPHENYL) 2H TETRAZOLIUM INNER SALT; CYCLIC AMP DEPENDENT PROTEIN KINASE; ENZYME INHIBITOR; REAGENT; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOASSAY; CANCER CELL CULTURE; CANCER SCREENING; CELL ASSAY; CELL PROLIFERATION; COLORIMETRY; CONTROLLED STUDY; CYTOTOXICITY; CYTOTOXICITY TEST; ENZYME INHIBITION; FLUORESCENCE; HUMAN; HUMAN CELL; IN VITRO STUDY; LABORATORY; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BIOLOGICAL ASSAY; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; TUMOR CELLS, CULTURED;

EID: 84934436012     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-577-4_14     Document Type: Article

References (35)

1. Almeida CA (2010) Cancer: basic science and clinical aspects. Wiley-Blackwell, London
2. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70
3. Altman R, Sarg M (2000) The cancer dictionary. Facts on File, New York, NY
4. Berg K, Zhai L, Chen M et al (1994) The use of watersoluble formazan complex to quantitate the cell number and mitochondrial function of Leishmania major promastigotes. Parasitol Res 80: 235-239
5. Malich G, Markovic B, Winder C (1997) The sensitivity and specificity of the MTS tetrazolium assay for detecting the in vitro cytotoxicity of 20 chemicals using human cell lines. Toxicology 124: 179-192
6. Matesic L, Locke JM, Bremner JB et al (2008) N-phenethyl and N-naphthylmethyl isatins and analogues as in vitro cytotoxic agents. Bioorg Med Chem 16: 3118-3124
7. Boyd MR, Paull KD (1995) Some practical considerations and applications of the National Cancer Institue in vitro anticancer drug discovery screen. Drug Dev Res 34: 91-109
8. Shoemaker RH (2006) The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6: 813-823
9. Collins JM (2012) Developmental therapeutics program NCI/NIH. http://dtp.nci.nih. gov. Accessed 29 Jun 2012
10. von Ahsen O, Bomer U (2005) Highthroughput screening for kinase inhibitors. Chembiochem 6: 481-490
11. Copeland RA (ed) (2005) Evaluation of enzyme inhibitors in drug discovery: a guide for medicinal chemists and pharmacologists (Methods in biochemical analysis). Methods of biochemical analysis. Wiley, Hoboken, NJ
12. Manning G, Whyte DB, Martinez R et al (2002) The protein kinase complement of the human genome. Science 298: 1912-1934
13. Goldstein D, Gray N, Zarrinkar P (2008) High-throughput kinase profiling as a platform for drug discovery. Nat Rev Drug Discov 7: 391-397
14. Liao JJL (2007) Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. J Med Chem 50: 409-424
15. Sharma P, Sharma R, Tyagi R (2008) Inhibitors of cyclin dependent kinases: useful targets for cancer treatment. Curr Cancer Drug Targets 8: 53-75
16. Skropeta D, Pastro N, Zivanovic A (2011) Kinase inhibitors from marine sponges. Mar Drugs 9: 2131-2154
17. Ono-Saito N, Niki I, Hidaka H (1999) H-series protein kinase inhibitors and potential clinical applications. Pharmacol Ther 82: 123-131
18. Shabb JB (2001) Physiological substrates of cAMP-dependent protein kinase. Chem Rev 101: 2381-2412
19. Chen AE, Ginty DD, Fan CM (2005) Protein kinase A signalling via CREB controls myogenesis induced by Wnt proteins. Nat Rev Drug Discov 433: 317-322
20. Tasken K, Aandahl EM (2004) Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol Rev 84: 137-167
21. Arnsten AFT, Ramos BP, Birnbaum SG et al (2005) Protein kinase A as a therapeutic target for memory disorders: rationale and challenges. Trends Mol Med 11: 121-128
22. Suzuki M, Shinohara F, Endo M et al (2009) Zebularine suppresses the apoptotic potential of 5-fl uorouracil via cAMP/PKA/CREB pathway against human oral squamous cell carcinoma cells. Cancer Chemother Pharmacol 64: 223-232
23. Putz T, Culig Z, Eder IE et al (1999) Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulinlike growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. Cancer Res 59: 227-233
24. Bryn T, Mahic M, Aandahl EM et al (2008) Inhibition of protein kinase A improves effector function of monocytes from HIV-infected patients. AIDS Res Hum Retroviruses 24: 1013-1015
25. Torgersen KM, Vang T, Abrahamsen H et al (2002) Molecular mechanisms for protein kinase A-mediated modulation of immune function. Cell Signal 14: 1-9
26. Indira CV, Matesic L, Locke JM et al (2012) Anti-cancer activity of an acid-labile N-alkylisatin conjugate targeting the transferrin receptor. Cancer Lett 316: 151-156
27. Zivanovic A, Pastro NJ, Fromont J et al (2011) Kinase inhibitory, haemolytic and cytotoxic activity of three deep-water sponges from North Western Australia and their fatty acid composition. Nat Prod Commun 6: 1921-1924
28. Promega (2009) Kinase-Glo ® luminescent kinase assay platform
29. Baki A, Bielik A, Molnar L et al (2007) A high through-put luminsescent assay for glycogen synthase kinase-3 beta inhibitors. Assay Drug Dev Technol 5: 75-83
30. Promega (2012) CellTiter 96 ® AQueous one solution cell proliferation assay. pp 1-13
31. PromegaCorporation (2012) Promega protocols. http://www.promega.com/ resources/ protocols. Accessed 26 Jul 2012
32. Moore GE, Woods LK (1967) Culture media for human cells - RPMI 1603, RPMI 1634, RPMI 1640 and GEM 1717. Tissue Cult Assn 3: 503-508
33. Moore GE, Gerner RE, Franklin HA (1967) Culture of normal human leukocytes. J Am Med Assoc 199: 519-524
34. Koresawa M, Okabe T (2004) Highthroughput screening with quantitation of ATP consumption: a universal nonradioisotope, homogeneous assay for protein kinase. Assay Drug Dev Technol 2: 153-160
35. Kashem MA, Nelson RM, Yingling JD et al (2007) Three mechanistically distinct kinase assays compared: measurement of intrinsic ATPase activity identified the most comprehensive set of ITK inhibitors. J Biomol Screen 12:70-83